A Phase 1, Open-Label Study of the Effects of Elagolix on Ovarian Activity, Ovulation and Ovarian Reserve in Premenopausal Women.
Phase of Trial: Phase I
Latest Information Update: 23 Feb 2018
At a glance
- Drugs Elagolix (Primary)
- Indications Endometriosis
- Focus Pharmacodynamics
- 23 Feb 2018 Results of population pharmacokinetics of elagolix from nine clinical studies ( five phase I and four phase III), published in the Clinical Pharmacokinetics
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Sep 2012 Planned End Date changed from 1 Nov 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.